Please assess the completion status of the following clinical trial:

Trial Title: Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive Advanced Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed breast cancer~  * Advanced disease~* Measurable disease, defined as ≥ 1 unidimensionally measurable lesion outside previously irradiated areas that is ≥ 20 mm OR ≥ 10 mm if the slice thickness of the CT scan or MRI is ≤ 5 mm~  * No nonmeasurable lesions as the only site of measurable disease, including any of the following:~    * Osteoblastic bone metastases~   * Ascites~   * Pleural or pericardial effusions~   * Carcinomatous lymphangitis of the lung~* Progressive disease after prior treatment with a nonsteroidal aromatase inhibitor (e.g., letrozole or anastrozole) in an adjuvant or advanced disease setting~* HER-2 amplification ≥ 2 by fluorescence in situ hybridization~* No clinical symptoms or history of CNS or leptomeningeal metastases (no imaging is required)~* No visceral involvement with risk for organ dysfunction~* Hormone receptor status:~  * Estrogen receptor- and/or progesterone receptor-positive tumor~PATIENT CHARACTERISTICS:~Age~* 18 and over~Sex~* Female~Menopausal status~* Postmenopausal, defined by 1 of the following:~  * At least 55 years of age~ * Less than 55 years of age with spontaneous cessation of menses for ≥ 1 year~ * Less than 55 years of age with spontaneous cessation of menses within the past year, but amenorrheic with biochemical evidence of postmenopausal status~ * Underwent prior bilateral oophorectomy~ * Radiation or chemically induced menopause (treatment with luteinizing hormone-releasing hormone antagonists must continue during study treatment)~Performance status~* WHO 0-1~Life expectancy~* Not specified~Hematopoietic~* WBC ≥ 3,000/mm\^3~* Platelet count ≥ 100,000/mm\^3~Hepatic~* AST and ALT ≤ 2 times upper limit of normal~Renal~* Creatinine clearance \> 30 mL/min~Cardiovascular~* No uncontrolled cardiac disease, including any of the following:~  * Unstable angina~ * Arrhythmia~ * Hypertension~* No history of congestive heart failure~* No myocardial infarction within the past 6 months~* LVEF \> 50% by echocardiogram~Pulmonary~* No severe dyspnea at rest~Other~* No other malignancy within the past 5 years except adequately treated carcinoma in situ of the cervix or localized nonmelanoma skin cancer~* No psychiatric disability that would preclude study participation or giving informed consent~* No active autoimmune disease~* No uncontrolled diabetes~* No other serious underlying medical condition that would preclude study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior trastuzumab (Herceptin®)~Chemotherapy~* Prior neoadjuvant or adjuvant chemotherapy allowed~* No prior palliative chemotherapy~Endocrine therapy~* See Disease Characteristics~Radiotherapy~* See Disease Characteristics~Surgery~* Not specified~Other~* More than 1 month since prior experimental drugs on another clinical trial~* No concurrent drugs that contraindicate study treatment~* No other concurrent anticancer drugs~* No other concurrent investigational drugs

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes once in weeks 1-3 OR once in week 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression after 9 weeks receive trastuzumab as before and oral letrozole once daily in the absence of further disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).